Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lack Of Lilly Litigation Clears Path For Pfenex’ Forteo Rival

Executive Summary

Pfenex says it can now launch its teriparatide in the US upon FDA approval, after Lilly failed to file a lawsuit in reaction to a Paragraph IV challenge to a Forteo device patent within the statutory timeframe.

Advertisement

Related Content

Alvogen And Pfenex Broaden Teriparatide Collaboration
Pfenex One Step Closer To Teriparatide As FDA Accepts NDA
Alvogen will market Pfenex’ teriparatide

Topics

Related Companies

What to read next

Advertisement
UsernamePublicRestriction

Register

GB140248

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel